vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与COMSCORE, INC.（SCOR）财务数据对比。点击上方公司名可切换其他公司
COMSCORE, INC.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.2倍（$93.5M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -1.5%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $2.9M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 3.8%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
PBYI vs SCOR — 直观对比
营收规模更大
SCOR
是对方的1.2倍
$75.5M
营收增速更快
PBYI
高出29.3%
-1.5%
自由现金流更多
PBYI
多$11.4M
$2.9M
两年增速更快
PBYI
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $93.5M |
| 净利润 | — | $3.0M |
| 毛利率 | 69.3% | 41.0% |
| 营业利润率 | 22.7% | 7.0% |
| 净利率 | — | 3.2% |
| 营收同比 | 27.7% | -1.5% |
| 净利润同比 | — | -3.7% |
| 每股收益（稀释后） | $0.26 | $9.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYISCOR
| Q4 25 | $75.5M | $93.5M | ||
| Q3 25 | $54.5M | $88.9M | ||
| Q2 25 | $52.4M | $89.4M | ||
| Q1 25 | $46.0M | $85.7M | ||
| Q4 24 | $59.1M | $94.9M | ||
| Q3 24 | $80.5M | $88.5M | ||
| Q2 24 | $47.1M | $85.8M | ||
| Q1 24 | $43.8M | $86.8M |
净利润PBYISCOR
| Q4 25 | — | $3.0M | ||
| Q3 25 | $8.8M | $453.0K | ||
| Q2 25 | $5.9M | $-9.5M | ||
| Q1 25 | $3.0M | $-4.0M | ||
| Q4 24 | — | $3.1M | ||
| Q3 24 | $20.3M | $-60.6M | ||
| Q2 24 | $-4.5M | $-1.7M | ||
| Q1 24 | $-4.8M | $-1.1M |
毛利率PBYISCOR
| Q4 25 | 69.3% | 41.0% | ||
| Q3 25 | 77.7% | 40.6% | ||
| Q2 25 | 76.5% | 40.6% | ||
| Q1 25 | 77.1% | 39.6% | ||
| Q4 24 | 76.4% | 42.4% | ||
| Q3 24 | 63.9% | 41.2% | ||
| Q2 24 | 77.4% | 39.5% | ||
| Q1 24 | 75.5% | 42.3% |
营业利润率PBYISCOR
| Q4 25 | 22.7% | 7.0% | ||
| Q3 25 | 17.6% | 1.9% | ||
| Q2 25 | 12.7% | -1.9% | ||
| Q1 25 | 8.7% | -2.4% | ||
| Q4 24 | 22.6% | 4.1% | ||
| Q3 24 | 27.4% | -67.4% | ||
| Q2 24 | -4.6% | -2.2% | ||
| Q1 24 | -5.3% | -2.2% |
净利率PBYISCOR
| Q4 25 | — | 3.2% | ||
| Q3 25 | 16.2% | 0.5% | ||
| Q2 25 | 11.2% | -10.6% | ||
| Q1 25 | 6.5% | -4.7% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | 25.2% | -68.5% | ||
| Q2 24 | -9.6% | -2.0% | ||
| Q1 24 | -11.0% | -1.2% |
每股收益（稀释后）PBYISCOR
| Q4 25 | $0.26 | $9.50 | ||
| Q3 25 | $0.17 | $-0.86 | ||
| Q2 25 | $0.12 | $-2.73 | ||
| Q1 25 | $0.06 | $-1.66 | ||
| Q4 24 | $0.40 | $-0.47 | ||
| Q3 24 | $0.41 | $-12.79 | ||
| Q2 24 | $-0.09 | $-1.19 | ||
| Q1 24 | $-0.10 | $-1.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $23.6M |
| 总债务越低越好 | $22.7M | $41.5M |
| 股东权益账面价值 | $130.3M | $111.4M |
| 总资产 | $216.3M | $407.7M |
| 负债/权益比越低杠杆越低 | 0.17× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资PBYISCOR
| Q4 25 | $97.5M | $23.6M | ||
| Q3 25 | $94.4M | $26.7M | ||
| Q2 25 | $96.0M | $26.0M | ||
| Q1 25 | $93.2M | $31.0M | ||
| Q4 24 | $101.0M | $29.9M | ||
| Q3 24 | $96.7M | $20.0M | ||
| Q2 24 | $96.8M | $14.7M | ||
| Q1 24 | $107.2M | $18.7M |
总债务PBYISCOR
| Q4 25 | $22.7M | $41.5M | ||
| Q3 25 | $34.0M | $41.4M | ||
| Q2 25 | $45.3M | $41.3M | ||
| Q1 25 | $56.7M | $41.3M | ||
| Q4 24 | $68.0M | $41.2M | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYISCOR
| Q4 25 | $130.3M | $111.4M | ||
| Q3 25 | $115.3M | $-26.3M | ||
| Q2 25 | $104.7M | $-21.7M | ||
| Q1 25 | $97.1M | $-13.5M | ||
| Q4 24 | $92.1M | $-8.3M | ||
| Q3 24 | $71.1M | $-2.7M | ||
| Q2 24 | $48.5M | $45.8M | ||
| Q1 24 | $51.0M | $51.4M |
总资产PBYISCOR
| Q4 25 | $216.3M | $407.7M | ||
| Q3 25 | $202.9M | $406.9M | ||
| Q2 25 | $194.9M | $415.9M | ||
| Q1 25 | $196.2M | $421.5M | ||
| Q4 24 | $213.3M | $430.2M | ||
| Q3 24 | $220.7M | $412.5M | ||
| Q2 24 | $205.0M | $474.1M | ||
| Q1 24 | $214.1M | $477.7M |
负债/权益比PBYISCOR
| Q4 25 | 0.17× | 0.37× | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $2.9M |
| 自由现金流率自由现金流/营收 | 19.1% | 3.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.07× |
| 过去12个月自由现金流最近4个季度 | $41.7M | $21.8M |
8季度趋势，按日历期对齐
经营现金流PBYISCOR
| Q4 25 | $14.4M | $3.2M | ||
| Q3 25 | $9.7M | $9.5M | ||
| Q2 25 | $14.1M | $932.0K | ||
| Q1 25 | $3.6M | $9.1M | ||
| Q4 24 | $15.6M | $-10.0M | ||
| Q3 24 | $11.0M | $12.5M | ||
| Q2 24 | $1.0M | $8.7M | ||
| Q1 24 | $11.2M | $6.9M |
自由现金流PBYISCOR
| Q4 25 | $14.4M | $2.9M | ||
| Q3 25 | $9.7M | $9.4M | ||
| Q2 25 | $14.1M | $787.0K | ||
| Q1 25 | $3.6M | $8.7M | ||
| Q4 24 | $15.6M | $-10.3M | ||
| Q3 24 | $11.0M | $12.4M | ||
| Q2 24 | $1.0M | $8.5M | ||
| Q1 24 | — | $6.6M |
自由现金流率PBYISCOR
| Q4 25 | 19.1% | 3.1% | ||
| Q3 25 | 17.7% | 10.5% | ||
| Q2 25 | 26.8% | 0.9% | ||
| Q1 25 | 7.7% | 10.1% | ||
| Q4 24 | 26.4% | -10.8% | ||
| Q3 24 | 13.7% | 14.0% | ||
| Q2 24 | 2.1% | 10.0% | ||
| Q1 24 | — | 7.6% |
资本支出强度PBYISCOR
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.1% | 0.4% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.0% | 0.3% |
现金转化率PBYISCOR
| Q4 25 | — | 1.07× | ||
| Q3 25 | 1.10× | 20.96× | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
